Pluri (NASDAQ:PLUR) Stock: Insider Alexandre Weinstein Manieu Acquires 833,334 Shares

Pluri Inc. (NASDAQ:PLUR) Director Alexandre Weinstein Manieu bought 833,334 shares of the firm’s stock in a transaction that occurred on Friday, October 23rd. The stock was bought at an average cost of $1.50 per share, for a total transaction of $1,250,001.00. Following the completion of the transaction, the director directly owned 2,083,334 shares of the company’s stock, valued at approximately $3,125,001. The trade was a 66.67% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Pluri Stock Performance

Pluri stock opened at $1.12 on Tuesday. Pluri Inc. has a 1 year low of $0.85 and a 1 year high of $4.87. The firm has a 50 day moving average price of $1.20 and a 200 day moving average price of $2.42. The company has a market cap of $14.12 million, a price-to-earnings ratio of -0.46 and a beta of 0.69.

Pluri (NASDAQ:PLUR) last posted its quarterly earnings results on Thursday, September 10th. The company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.12. The company had revenue of $0.34 million for the quarter, compared to analysts’ expectations of $0.66 million.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded Pluri from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 26th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, Pluri currently has a consensus rating of “Sell”.

About Pluri

Pluri Inc is a biotechnology company developing cell-based products and technologies for applications in human health, food production and other industries. The company’s platform uses three-dimensional cell expansion technology designed to grow cells at commercial scale without genetic modification.

Pluri’s health-related research has historically focused on placenta-derived, off-the-shelf cell therapies, including its PLX product candidates, which have been investigated for potential use in conditions involving inflammation, tissue damage and impaired blood flow.